US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB9 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said ...
Sanofi blockbuster drug wins clearance in US for lung disease
WEB7 hours ago · Bloomberg. Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators. The US Food ...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB6 hours ago · SNY. REGN. GLDAF. The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB9 hours ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB9 hours ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
WEB2 hours ago · News; Company News; Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD. By Andrew Kessel. Published September 27, 2024. 04:51 PM EDT. ALAIN JOCARD / Contributor / Getty Images. Key Takeaways.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB23 hours ago · European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over ...
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB23 hours ago · Green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD. Regeneron REGN 1.83%increase; green up pointing ...
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients.
Press Room - Sanofi US News
WEBMay 10, 2024 · FDA approves updated ALTUVIIIO® label with expanded pediatric data confirming highly effective bleed protection in children with hemophilia A. Full results from the pivotal XTEND-Kids study added to the US label, building on the interim data included in the 2023 FDA approval. ALTUVIIIO is a first-in-class, high-sustained factor VIII ...
Skip to content